Jersey R & O 7864

 

Misuse of Drugs (Jersey) Law, 1978

____________

 

MISUSE OF DRUGS (DESIGNATION) (JERSEY) ORDER, 1989

____________

THE PUBLIC HEALTH COMMITTEE, in pursuance of Articles 10 and 25 of the Misuse of Drugs (Jersey) Law, 1978,1 as amended (hereinafter referred to as “the Law”) and after consultation with the Advisory Council on the Misuse of Drugs, hereby orders as follows –

1.-(1)  The controlled drugs specified in Part I of the Schedule to this Order are hereby designated as drugs to which paragraph (4) of Article 10 of the Law applies.

(2)     The controlled drugs specified in Part II of the Schedule to this Order are excepted from Part I of that Schedule.

2.             The Misuse of Drugs (Designation) (Jersey) Order, 19802 and the Misuse of Drugs (Designation) (Amendment) (Jersey) Order, 19853 are revoked.

3.             This Order may be cited as the Misuse of Drugs (Designation) (Jersey) Order, 1989 and shall come into force on the first day of March, 1989.

By Order of the Public Health Committee,

 

E.J.M. POTTER

 

Greffier of the States.

4th January, 1989.

SCHEDULE

PART I

Controlled drugs to which paragraph (4) of Article 10 of the Law applies

1.             The following substances and products, namely –

 

(a)	Amphetamine	Lysergide and other N-alkyl derivatives of lysergamide
	Bufotenine
	Cannabinol	Mescaline
	Cannabinol derivatives	Methylamphetamine
	Cannabis	Psilocin
	Cannabis resin	Raw opium
	Cathinone	Rolicyclidine
	Coca leaf	Tenocyclidine
	Concentrate of poppy-straw	4-Bromo-2, 5-dimethoxy- -methyl-phenethylamine
	Eticyclidine	N.N-Diethyltryptamine
	Lysergamide	N.N-Dimethyltryptamine
		2.5-Dimethoxy-a,4-dimethyl-phenethylamine

(b)     any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c)     any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, a-methylphenethylamine, an N-alkyl-a-methylphenethylamine, a-ethylphenethylamine, or an N-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;

(d)     any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say –

(i)      by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii)     by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii)    by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv)    by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v)     by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi)    by replacement of the N-propionyl group by another acyl group;

(e)     any compound (not being a compound for the time being specified in Part II of this Schedule) that is structurally derived from pethidine by modification in any of the following ways, that is to say –

(i)      by replacement of the 1-methyl group by an acyl alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii)     by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii)    by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv)    by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v)     by formation of an N-oxide or of a quaternary base.

2.             Any stereoisomeric form of a substance specified in paragraph 1 above.

3.             Any ester or ether of a substance specified in paragraph 1 or 2 above.

4.             Any salt of a substance specified in any of paragraphs 1 to 3 above.

5.             Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 above.

PART II

Controlled drugs excepted from Part I

1.             The compounds referred to in paragraph 1(d) of Part I of this Schedule are –

Alfentanil

Carfentanil

Lofentanil

Sufentanil.

2.             The compounds referred to in paragraph 1(e) of Part I of this Schedule are –

Allylprodine

Alphameprodine

Alphaprodine

Anileridine

Betameprodine

Betaprodine

Hydroxypethidine

Properidine

Trimeperidine.